Infinium Pharmachem Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/updn1azn8xkiykuhvvdcr8gj.pdf

Key Takeaways


The US Iodine JV: Supply Security Meets Technology

Nilesh Patel: "Our JV partner has cracked this limitation, barriers And with the air desorption technology, we can easily produce 99.9% purity Iodine with very minimum investment which we have made."

Contrast Media: The Next Growth Leg


Financial Performance & Margin Trajectory


Customer Base & Business Model

Sanjay Patel: "It's not absolutely crams model, just a little bit modified version of crams. But our focus remains the same. That is iodine chemistry and iodination only."

Other Businesses & Strategic Moves


What Management Declined to Answer


Guidance & Commitments

CommitmentSpecificsTimeline
US JV commercial productionFirst commercial output from IBL ElementsBy 31 December 2024
Contrast media project completionCapex project finished and ready for launchBy 31 March 2025
Contrast media year-one revenue₹30–40 crore from the new segmentFY26
Top-line target₹200+ crore revenue with ~10% sustainable PAT marginBy FY26
Capacity utilizationAt least 400 metric tonnes (up from 293 in FY24)Within next 2 years
REACH registrations16 products registeredBy end of calendar 2024
Biocoal production10,000 metric tonnes from Infinium Green EnergyWithin next 1–2 years
Iodine consumption (Vision 2030)800 to 1,000 metric tonnesBy 2030
Market share (Vision 2030)Approximately 25%By 2030

Key Metrics

MetricQ4 FY24
Revenue from operations₹135.66 cr, +19% YoY
H2 FY24 revenue₹74.18 cr, +21% vs H1
Gross profit margin24% for FY24; 21% for H2
EBITDA margin15% for FY24, nearly doubled over 5 years
PAT₹11.50 cr for FY24
PAT CAGR (5-year)90%
Revenue CAGR (5-year)36.71%
Iodine derivatives production293 metric tonnes in FY24, installed capacity 1,800 metric tonnes
Capacity utilization target400 metric tonnes within next 2 years
Customer count332 customers in FY24, up from 274 the prior year
Revenue from intermediates97–98% of total revenue
Top 10 client concentration61.86% of revenue
Iodine market share (India)~12% currently; target ~25% by 2030
US JV iodine supply100 metric tonnes per annum, 30-year agreement
US JV payback period3.5 to 4 years
Contrast media capex₹11 cr total; completion by March 31, 2025
Contrast media revenue target₹30–40 cr in FY26 (Year 1)
Contrast media EBITDA margin29–30% (industry study)
Long-term EBITDA margin target22–25%
Term loan outstanding₹4.8 cr as of March 31, 2024; no further term loans
Infinium Pharmachem stake in Infinium Healthcare57% currently; may increase to ~75%